Response

TO THE EDITOR
We thank our Spanish colleagues for adding their experience on purine analog-and chlorambucil-induced apoptosis in B cell chronic lymphocytic leukemia (CLL), at clinically achievable drug doses. In order to validate Castejon's suggestion, concerning the possibility of predicting a clinical reponse to treatment with an apoptosis in vitro assay, we extended our experience and we will report here our additional data.
Applying the Castejon's definition of in vitro response by the calculation of the drug-induced/spontaneous apoptosis ratio, we investigated the possible correlation between the in vitro response to fludarabine and the clinical outcome in six previously untreated CLL patients. These results are summarized in Table 1 : patients with a fludarabineinduced/spontaneous apoptosis ratio lower than 1.8 failed to clinically respond to the purine analog, as evaluated by reduction of the total tumor mass (TTM) score. 1 On the other hand, a very high apoptosis ratio was able to predict, at least in this small cohort of patients, a very good complete response to fludarabine. Therefore, we would like to support Castejon's conclusion stating that the possibility of predicting clinical response to treatment by an apoptosis in vitro assay has been opened in CLL. cally higher in early and advanced stages in typical CLL compared to CLL/PL (P Ͻ 0.003 and P = 0.002, respectively) or PLL (P Ͻ 0.03 and P = 0.01, respectively). No significant difference was found between C3 serum level in early and advanced stage typical CLL (P = 0.28) or between CLL/PL and PLL (P = 0.59). Similar results were found in C4 component serum levels. C4 level was higher in early and advanced stages in typical CLL than in CLL/PL (P Ͻ 0.01 and P Ͻ 0.006) or in PLL (P = 0.01 and P Ͻ 0.006, respectively). No significant differences were found between C4 serum level in early and advanced stage typical CLL (P = 0.37) and between CLL/PL and PLL (P = 0.64) ( Table 1) . Eleven patients (three PLL, one CLL/PL and seven CLL) disclosed a significant decrease in their C3 and/or C4 values during the course of the disease to more advanced stage (five cases) and/or PL transformation, with development of AIHA (five cases) or ITP (one case). Patients with low serum C3/C4 level had high frequency of autoimmune phenomena (AIHA, vasculitis, monoclonal gammopathy). Low complement level was found in eight out of 21 patients who developed AIHA, three out of five with vasculitis, five out of 14 with monoclonal peak. Complement level at diagnosis had a prognostic significance in our group of patients. Median survival was 94 months in the patients presenting with normal C3 and C4 values compared to 67 months with low serum complement.
In conclusion, we did not find a correlation between C3 and C4 level and clinical stage of CLL. However, our data suggest that hypocomplementemia correlates with lymphocyte activation and differentiation stage in chronic lymphoproliferative diseases. Low serum complement level in CLL and PLL is associated with autoimmune features and poor prognosis.
The complement system in chronic B cell lymphoproliferative disorders
Shvidel et al report a study of the C3 and C4 serum complement levels in chronic lymphoproliferative diseases of the B cell type. They found a correlation between hypocomplementemia lymphocyte activation and differentiation stage, the presence of auto immune features and prognosis, but not with the clinical stage of the disease. Their observations tend to confirm the importance of the complement system in B cell lymphoproliferative disorders. Our study 1 of the complement system in chronic lymphocyte leukemia (CLL), in which we checked all the serum component levels of the three main pathways, showed a correlation between hypocomplementemia and predisposition to auto immune features in CLL patients, but also with the stage of the disease and the tendency to develop severe life-threatening infections.
A similarly pathological complement system was found Rehovot, Israel among first degree relatives of CLL patients, thus raising the hypothesis of a hereditary background for hypocomplementemia in CLL. We are currently conducting a study of the complement system, including activation of the three main pathways, in a cohort of multiple myeloma patients. This study could improve our understanding of the role of the complement system in chronic lymphoproliferative disorders and its correlation with lymphocyte activation and differentiation stage.
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